Coumou Jeroen, Wagemakers Alex, Trentelman Jos J, Nijhof Ard M, Hovius Joppe W
Center for Experimental and Molecular Medicine, Academic Medical Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.
Institute for Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
PLoS One. 2015 Apr 28;10(4):e0123495. doi: 10.1371/journal.pone.0123495. eCollection 2014.
Human tick-borne diseases that are transmitted by Ixodes ricinus, such as Lyme borreliosis and tick borne encephalitis, are on the rise in Europe. Diminishing I. ricinus populations in nature can reduce tick exposure to humans, and one way to do so is by developing an anti-vector vaccine against tick antigens. Currently, there is only one anti-vector vaccine available against ticks, which is a veterinary vaccine based on the tick antigen Bm86 in the gut of Rhipicephalus microplus. Bm86 vaccine formulations cause a reduction in the number of Rhipicephalus microplus ticks that successfully feed, i.e. lower engorgement weights and a decrease in the number of oviposited eggs. Furthermore, Bm86 vaccines reduce transmission of bovine Babesia spp. Previously two conserved Bm86 homologues in I. ricinus ticks, designated as Ir86-1 and Ir86-2, were described. Here we investigated the effect of a vaccine against recombinant Ir86-1, Ir86-2 or a combination of both on Ixodes ricinus feeding. Recombinant Ixodes ricinus Bm86 homologues were expressed in a Drosophila expression system and rabbits were immunized with rIr86-1, rIr86-2, a combination of both or ovalbumin as a control. Each animal was infested with 50 female adults and 50 male adults Ixodes ricinus and tick mortality, engorgement weights and egg mass were analyzed. Although serum IgG titers against rIr86 proteins were elicited, no effect was found on tick feeding between the rIr86 vaccinated animals and ovalbumin vaccinated animals. We conclude that vaccination against Bm86 homologues in Ixodes ricinus is not an effective approach to control Ixodes ricinus populations, despite the clear effects of Bm86 vaccination against Rhipicephalus microplus.
由蓖麻硬蜱传播的人类蜱传疾病,如莱姆病和蜱传脑炎,在欧洲呈上升趋势。自然界中蓖麻硬蜱数量的减少可以降低蜱与人类的接触,实现这一目标的一种方法是研发针对蜱抗原的抗媒介疫苗。目前,仅有一款针对蜱的抗媒介疫苗,它是一种基于微小牛蜱肠道中蜱抗原Bm86的兽用疫苗。Bm86疫苗制剂可使成功取食的微小牛蜱数量减少,即饱血重量降低,产卵数量减少。此外,Bm86疫苗还能减少牛巴贝斯虫属的传播。此前已描述了蓖麻硬蜱中两个保守的Bm86同源物,分别命名为Ir86-1和Ir86-2。在此,我们研究了针对重组Ir86-1、Ir86-2或二者组合的疫苗对蓖麻硬蜱取食的影响。重组蓖麻硬蜱Bm86同源物在果蝇表达系统中表达,用rIr86-1、rIr86-2、二者组合或卵清蛋白作为对照对兔子进行免疫。每只动物接种50只成年雌性蓖麻硬蜱和50只成年雄性蓖麻硬蜱,并分析蜱的死亡率、饱血重量和卵块情况。尽管诱导产生了针对rIr86蛋白的血清IgG滴度,但在接种rIr86疫苗的动物和接种卵清蛋白疫苗的动物之间,未发现对蜱取食有影响。我们得出结论,尽管Bm86疫苗对微小牛蜱有明显效果,但针对蓖麻硬蜱中Bm86同源物的疫苗接种并非控制蓖麻硬蜱种群数量的有效方法。